

Loss of the Spectraplakin Short Stop Activates the DLK Injury Response Pathway in *Drosophila*

Vera Valakh,¹ Lauren J. Walker,¹ James B. Skeath,² and Aaron DiAntonio¹

¹Department of Developmental Biology, Hope Center for Neurological Disorders, and ²Department of Genetics, Washington University School of Medicine, St. Louis, Missouri 63110

The MAPKKK dual leucine zipper-containing kinase (DLK, Wallenda in *Drosophila*) is an evolutionarily conserved component of the axonal injury response pathway. After nerve injury, DLK promotes degeneration of distal axons and regeneration of proximal axons. This dual role in coordinating degeneration and regeneration suggests that DLK may be a sensor of axon injury, and so understanding how DLK is activated is important. Two mechanisms are known to activate DLK. First, increasing the levels of DLK via overexpression or loss of the PHR ubiquitin ligases that target DLK activate DLK signaling. Second, in *Caenorhabditis elegans*, a calcium-dependent mechanism, can activate DLK. Here we describe a new mechanism that activates DLK in *Drosophila*: loss of the spectraplakin *short stop* (*shot*). In a genetic screen for mutants with defective neuromuscular junction development, we identify a hypomorphic allele of *shot* that displays synaptic terminal overgrowth and a precocious regenerative response to nerve injury. We demonstrate that both phenotypes are the result of overactivation of the DLK signaling pathway. We further show that, unlike mutations in the PHR ligase Highwire, loss of function of *shot* activates DLK without a concomitant increase in the levels of DLK. As a spectraplakin, Shot binds to both actin and microtubules and promotes cytoskeletal stability. The DLK pathway is also activated by downregulation of the TCP1 chaperonin complex, whose normal function is to promote cytoskeletal stability. These findings support the model that DLK is activated by cytoskeletal instability, which is a shared feature of both spectraplakin mutants and injured axons.

Introduction

A conserved signaling pathway featuring the PHR ubiquitin ligase and its target, the MAPKKK DLK, regulates both neural circuit development and the axon injury response pathway (Tian and Wu, 2013). In *Drosophila*, loss of the PHR ligase Highwire leads to a dramatic expansion of the neuromuscular junction (NMJ) (Wan et al., 2000; DiAntonio et al., 2001) and promotes both proximal axon regeneration and distal axon degeneration in response to nerve injury (Xiong et al., 2010, 2012). The PHR ligase is conserved in worms and mice, where it also regulates circuit development (Schaefer et al., 2000; Zhen et al., 2000; Bloom et al., 2007; Lewcock et al., 2007; Culican et al., 2009) and the response to nerve injury (Nix et al., 2011; Babetto et al., 2013). The Highwire ligase targets the MAPKKK Wallenda/DLK, and in *highwire* mutants the levels of Wallenda/DLK rise and the downstream JNK/Fos pathway is overactivated (Collins et al., 2006). A

series of recent studies demonstrate that DLK is a central component of an evolutionarily conserved axon injury response pathway, regulating both axon regeneration (Hammarlund et al., 2009; Yan et al., 2009; Xiong et al., 2010; Shin et al., 2012) and axon degeneration (Miller et al., 2009; Xiong and Collins, 2012). Despite the clear importance of DLK after nerve injury, our understanding of how DLK/Wallenda is activated *in vivo* is limited.

To date, two methods for activating DLK have been described. First, DLK is activated when its levels rise because of transgenic overexpression, loss of the PHR ligase, or JNK activation (Nakata et al., 2005; Collins et al., 2006; Huntwork-Rodriguez et al., 2013). Second, in *Caenorhabditis elegans*, an elegant Ca²⁺-dependent mechanism activates the DLK ortholog DLK-1 (Yan and Jin, 2012). Mammalian and *Drosophila* DLK, however, lack the hexapeptide sequence that mediates this form of regulation, suggesting that additional DLK activation mechanisms exist.

In this study, we demonstrate that the *Drosophila* spectraplakin *short stop* (*shot*) inhibits the activation of Wallenda/DLK. Spectraplakins are large multidomain proteins that cross-link actin and microtubules to regulate cytoskeletal dynamics (Suozzi et al., 2012). Previously described *shot* alleles are embryonic lethal, have disrupted microtubule dynamics, and exhibit severe defects in axon outgrowth (Lee and Kolodziej, 2002; Bottenberg et al., 2009; Alves-Silva et al., 2012). Here we identify a viable loss-of-function allele of *shot* that displays dramatic synaptic terminal overgrowth at the NMJ. In this mutant, the Wallenda/DLK pathway is overactivated leading to both NMJ overgrowth and enhanced response to axonal injury, yet unlike in *highwire* mutants, the levels of Wallenda/DLK are not elevated. These observations

Received May 23, 2013; revised Oct. 2, 2013; accepted Oct. 7, 2013.

Author contributions: V.V. and A.D. designed research; V.V. and L.J.W. performed research; J.B.S. contributed unpublished reagents/analytic tools; V.V. analyzed data; V.V. and A.D. wrote the paper.

This work was supported by National Institutes of Health Grants DA020812 and NS065053 to A.D. and Grant NS036570 to J.B.S. We thank members of the A.D. laboratory for helpful discussions and especially Sylvia Johnson for the help with the initial screening; Dr. Andreas Prokop for providing the rescue constructs; the Bloomington Stock Center (Indiana University) and the Vienna Drosophila RNAi Center for providing additional stocks; and the Developmental Studies Hybridoma Bank (University of Iowa) for antibodies.

The authors declare no competing financial interests.

Correspondence should be addressed to Dr. Aaron DiAntonio, Department of Developmental Biology, Washington University School of Medicine, Campus Box 8103, 660 S. Euclid, St. Louis, MO 63110. E-mail: diantonio@wustl.edu.

DOI:10.1523/JNEUROSCI.2196-13.2013

Copyright © 2013 the authors 0270-6474/13/3317863-11\$15.00/0

suggest a model in which tonic cytoskeletal destabilization in the *shot* mutant activates Wallenda/DLK without altering its levels. In support of this model, mutations in the TCP1 chaperonin complex, which is also required for stability of the tubulin and actin cytoskeleton (Ursic et al., 1994; Grantham et al., 2006), also activate DLK signaling. These findings led us to speculate that axonal injury activates DLK via acute cytoskeletal destabilization.

Materials and Methods

Fly stocks. Flies were maintained at 25°C on standard fly food. We used the following fly stocks in our studies: Canton S (WT), *elav-Gal4* (Yao and White, 1994), *24B-Gal4* (Brand and Perrimon, 1993), *BG380-Gal4* (Sanyal, 2009), *m12-Gal4* (P(GAL4)5053A) (Klapper, 2000), *wnd²* and *wnd³* (Collins et al., 2006), *UAS-bsk^{DN}* (Weber et al., 2000), *UAS-fos^{DN}*(Fbz) (Eresh et al., 1997), and *puc-LacZ* (Martín-Blanco et al., 1998). The following fly lines were obtained from the Bloomington Stock Center: *shot³* (Kolodziej et al., 1995), the deficiency line Df(2R)BSC383, *shot* RNAi line P{TriP.GL01286}attP2, *TCP1 α* and *TCP1 β* RNAi lines, *shot* rescue constructs *UAS-shot L(A)-GFP* (*shot-FL* in this paper), *UAS-shot L(C)-GFP* (*shot- Δ Calponin* in this paper), *UAS-shot L(A)-DeltaEF-hand-GFP* (*shot- Δ EF*), *UAS-shot L(A)-DeltaPlakin-GFP* (*Shot- Δ Plakin*), *UAS-shot L(A)-Deltarod1-GFP* (*shot- Δ Rod*) (Bottenberg et al., 2009), *UAS-EB1-GFP*, and *ppk-Gal4*. *UAS-shot L(A)-DeltaGAS2-GFP* (*shot- Δ Gas2*) was obtained from Andreas Prokop. *UAS-wnd* RNAi and RNAis against *neurologin* and *CG18278* were obtained from Vienna RNAi stock center (Dietzl et al., 2007).

Immunohistochemistry. Third-instar larvae were dissected in PBS and fixed in either Bouin's fixative for 5 min or 4% formaldehyde for 20 min on ice. Larvae were washed with PBS containing 0.1% Triton X-100 (PBT) and blocked in 5% NGS in PBT for 30 min, followed by overnight incubation in primary antibodies in 5% NGS in PBT, three washes in PBT, incubation in secondary antibodies in 5% NGS in PBT for 45 min, three final washes in PBT, and equilibration in 70% glycerol in PBS. Samples were mounted in VectaShield (Vector). The following primary antibodies were used: mouse α -Brp, 1:500 (Developmental Studies Hybridoma Bank), mouse α -Dlg monoclonal antibody (mAb) 4f3, 1:2000 (Developmental Studies Hybridoma Bank), rabbit α -DGLuRIII, 1:2500 (Marrus et al., 2004), rabbit α -DVGLUT, 1:10,000 (Daniels et al., 2004), rat anti-Elav, 1:50 (7E8A10; Developmental Studies Hybridoma Bank), mouse anti-LacZ, 1:100 (40-1a; Developmental Studies Hybridoma Bank), rabbit α -Wallenda (Collins et al., 2006), and A488 rabbit anti-GFP, 1:1000 (Invitrogen). Goat Cy5-, Cy3-, and FITC-conjugated secondary antibodies against mouse and rabbit IgG were used at 1:1000 and were obtained from Jackson ImmunoResearch Laboratories. Antibodies obtained from the Developmental Studies Hybridoma Bank were developed under the auspices of the National Institute of Child Health and Human Development and maintained by the Department of Biological Sciences of the University of Iowa, Iowa City, Iowa.

Western blot. Third-instar larval brains were homogenized in ice-cold homogenization buffer (67 mM Tris-HCl, pH 8.0, 67 mM NaCl, 2 M urea, 1 mM EDTA, and 1.3% SDS), and samples were run on 15% SDS-PAGE gels according to standard procedures (Wu et al., 2005). Rabbit α -Wallenda was used at 1:100. Mouse α -Armadillo (Developmental Studies Hybridoma Bank) was used at 1:20. HRP-conjugated goat α -rabbit and α -mouse (Jackson ImmunoResearch Laboratories) were used at 1:10,000.

Imaging and analysis. Samples were imaged using a Nikon C1 confocal microscope using 40 \times (for VNC images) or 60 \times (for NMJs) objectives. All genotypes for an individual experiment were imaged at the same gain and set such that signals from the brightest genotype for a given experiment were not saturating. Both male and female larvae were used for each experiment. To quantify the mean intensity of *puc-lacZ* expression, the nuclei along the dorsal midline of the ventral nerve cords were selected by the staining for Elav. *puc-lacZ* is localized to the nuclei in those cells because of the NLS sequence fusion. The nuclei from at least 9 animals per genotype were measured and then normalized to control. To quantify Wallenda intensity in the neuropil of larval VNCs, the region was selected based on the BRP staining. At least eight larvae were used per

genotype and the staining intensity was normalized to WT. Statistical analysis was performed and graphs were generated using Origin 7.0 (Origin Laboratory). ANOVA was used for comparison of samples within an experimental group. All histograms and measurements are shown as mean \pm SEM.

Live imaging. Wandering third-instar larvae were mounted on a slide between a sylgard cushion and a coverslip, which was held in place with orthodontic rubber bands. Live imaging was performed on a Quorum spinning disc confocal/ 1X8-1-Olympus inverted microscope equipped with a Hamamatsu 69100-13 camera and MetaMorph acquisition software. Time-lapse movies were taken at one frame per 2 s using a 40 \times air objective (NA 0.75). Analysis of microtubule dynamics was modified from Chen et al. (2012). Briefly, the number of EB1 comets was counted within 50 μ m dendritic segments beginning 10 μ m from the cell body of multidendritic sensory neurons. Quantification was based on three consecutive in-focus frames. RNAi against *CG18278* was used as a control. At least two dendritic segments were averaged for each cell, blinded to genotype. ImageJ software was used for image analysis.

Nerve crush assay and analysis. Larvae were positioned on their trachea with the ventral nerves closest to the top surface, and then segmental nerves were pinched tightly through the cuticle for 10 s with Dumostar number 5 forceps. Larvae were transferred to a grape plate with inactivated yeast and water mixture and kept alive for 7 h at 23°C. Pinched larvae were then dissected and stained for the growth cone analysis, which was modified from Xiong et al. (2010). Stained crushed proximal stumps were analyzed for the presence of a growth cone while blinded to the genotype. To score a growth cone as sprouting, the axons must have at least five visible sprouts. Then, all analyzed crushed axons were combined for each genotype, and the fraction of sprouting stumps was generated. At least 12 larvae with a minimum of 55 nerves were analyzed for each genotype. χ^2 test was performed to assess statistically significant differences among the genotypes.

Results

Short stop is required for normal synaptic terminal growth at the larval NMJ

To identify novel regulators of synaptic development, we conducted an anatomical screen on a subset of EMS mutants preselected for adult lethality or abnormalities in larval or adult locomotion. Third-instar larvae were dissected and stained with antibodies against the active zone component Bruchpilot (Wagh et al., 2006) and the essential glutamate receptor subunit DGluRIII (Marrus et al., 2004). We assessed various aspects of synaptic development, including the apposition of presynaptic active zones and postsynaptic glutamate receptor clusters, synaptic terminal overgrowth and undergrowth, and synaptic maintenance (Valakh et al., 2012). We focus here on a mutant that displayed dramatic NMJ overgrowth. The phenotype is apparent when visualizing terminal morphology by staining for the postsynaptic scaffolding protein Discs-large, the synaptic vesicle protein DVGLUT, and the presynaptic membrane as visualized by an antibody to HRP (Fig. 1A). Although the NMJ overgrowth is present at the synapse on every muscle, the number of synaptic boutons was quantified at the well-characterized muscle 4 type Ib NMJ. Mutant NMJs contain approximately twice as many boutons as in wild-type (WT) (Fig. 1A,C). To identify the gene responsible for the synaptic phenotype, we performed meiotic recombination and deficiency mapping and identified a small region in the second chromosome (50C6–50D2) that contains 34 genes. We then took a candidate approach, focusing on *short stop* (*shot*), a large gene in the region with a known function in neurons. The well-characterized null allele of *shot*, *shot³* (Röper and Brown, 2003), failed to complement our new mutant, demonstrating that it is a new allele of *shot*. We name this new allele *shot^{vv}*. Because *shot^{vv}* is viable as a third-instar larvae, while all previously described alleles of *shot* are embryonic lethal, this new




Figure 1. Synaptic terminal overgrowth at the NMJs in the *shot* mutant. **A**, Sample confocal images of muscle 4 type Ib NMJs of WT, *shot^{VV}/shot^{VV}* (*shot^{VV}*), *shot^{VV}/shot³* and *UAS-shot-FL-GFP/+shot^{VV}/shot³; elav-Gal4/+ (shot^{VV}/shot³ + rescue)* stained for the postsynaptic DLG (red), presynaptic DVGLUT (green), and the membrane marker HRP (blue). Scale bar, 50 μ m. **B**, Sample confocal images of muscle 4 type Ib NMJs of *UAS-dcr2, elav-Gal4/UAS-shot-RNAi* (Neuronal *shot* RNAi), and *UAS-dcr2; G7-Gal4/+; UAS-shot-RNAi/+* (Muscle *shot* RNAi). Muscle 4 type Ib bouton number of the genotypes listed in **A** are quantified in **C**. ** $p < 0.001$, compared with WT. * $p < 0.05$, compared with WT. Phenotypes listed in **B** with addition of *UAS-dcr2; elav-Gal4/+* (control) were quantified in **D**. ** $p < 0.001$, compared with control. $n > 15$ for each genotype. Error bars indicate SEM.

allele is likely a hypomorph. However, the NMJ overgrowth phenotype of *shot^{VV}/shot³* is only slightly stronger than that of *shot^{VV}* alone (Fig. 1A, C), suggesting that the *shot^{VV}* allele is a relatively strong loss-of-function mutant, at least for its role in regulating NMJ terminal growth. We use the combination of *shot^{VV}/shot³* for all subsequent experiments to avoid issues of second site mutations, and we will refer to this genotype as *shot*.

To test whether the synaptic overgrowth phenotype of *shot* is due to the absence of WT *shot*, we used the *UAS/Gal4* system to express transgenic Shot in a tissue-specific manner. Expression of a full-length long isoform Shot-FL (Bottenberg et al., 2009) with the neuronal driver *elav-Gal4* in the *shot^{VV}/shot³* mutant background rescues the synaptic terminal overgrowth (Fig. 1A, C). In contrast, muscle expression of the same transgene with the strong muscle driver 24B-Gal4 was unable to rescue the phenotype. Hence, the NMJ overgrowth results from the loss of *shot* function and *shot* is required in neurons for normal synaptic development.

Because the nature of the mutation in *shot^{VV}* allele is unknown, we wanted to test whether loss of function of *shot* is sufficient to induce the overgrowth phenotype. Driving a transgenic RNAi targeting *shot* with the neuronal driver *elav-Gal4* leads to an expansion of the NMJ that is very similar to that of the genetic mutant (Fig. 1B). Knockdown of *shot* in the muscle does not result in a synaptic phenotype (Fig. 1B, D). These data indicate that loss of function of *shot* in the nervous system is sufficient to cause synaptic overgrowth.

The Rod and Plakin domains are dispensable for the function of Shot in restraining NMJ growth

Spectraplakins are comprised of an N-terminal Calponin domain, a Plakin domain, a long rod domain with multiple Spectrin repeats, and a C-terminal EF hand and microtubule-binding growth arrest-specific 2 (Gas2) domain (Röper et al., 2002). Spectraplakins perform different functions in different tissues, and domains that are crucial in one context may be dispensable in another (Bottenberg et al., 2009). To investigate the structural requirements of Shot for NMJ growth, we used a series of transgenes that express GFP-tagged *shot* mutants that were previously generated lacking individual domains (Lee and Kolodziej, 2002, Bottenberg et al., 2009); the structures of the transgenes are schematized in Figure 2A. For each deletion variant, we tested for transport of GFP-Shot out of the cell bodies and into the axons as well as genetic rescue of the *shot* NMJ overgrowth phenotype. We find that the full-length Shot, Shot-FL, is abundant in axons. We see similar axonal localization of Shot- Δ Calponin, which lacks one actin-binding Calponin homology domain, Shot- Δ Rod, lacking the large Spectrin repeat rod domain, and Shot- Δ Plakin, which lacks the large Plakin domain (Fig. 2B). However Shot- Δ EF, in which the Ca^{2+} binding EF hand domain is deleted, and Shot- Δ Gas2, in which the microtubule-binding Gas2 domain is deleted, show very little axonal accumulation (Fig. 2B). Shot- Δ EF shows strong expression in cell bodies (data not shown), suggesting that this calcium-binding EF hand domain may be required for efficient transport of Shot into the axon.




Figure 2. Rescue constructs missing the Rod domain and Plakin domain rescue the NMJ overgrowth phenotype of *shot*. **A**, Schematic representation of Short Stop and the deletion constructs. Shot Δ Calponin is a Shot C isoform, which lacks one of the two Calponin homology domains. The rest of the constructs were derived from Shot A isoform represented in **A** as Shot FL (full-length). All constructs are COOH GFP-tagged. **B**, Sample confocal images of two nerves in the larvae expressing deletion constructs with the strong neuronal driver *BG380-Gal4* in the WT background. The nerves are stained for GFP (green) to label the expression of the constructs and HRP (red) to label the neuronal membrane. Scale bar, 50 μ m. **C**, Quantification of the muscle 4 type Ib bouton number in *elav-Gal4/+* (Control), *UAS-shot-FL/+*; *elav-Gal4/+* (shot FL o/e), *shot^{vu}/shot³*; *elav-Gal4/+* (shot), *UAS-shot-FL*; *shot^{vu}/shot³*; *elav-Gal4/+* (shot + Shot FL), *shot^{vu}/shot³*, *UAS-shot- Δ Calponin*; *elav-Gal4/+* (shot + Δ Calponin), *UAS-shot- Δ Gas2/+*; *shot^{vu}/shot³*; *elav-Gal4/+* (shot + Δ Gas2), *shot^{vu}/shot³*, *UAS-shot- Δ EFHand*; *elav-Gal4/+* (shot + Δ EF); *shot^{vu}/shot³*, *UAS-shot- Δ Rod1*; *elav-Gal4/+* (shot + Δ Rod), *shot^{vu}/shot³*, *UAS-shot- Δ Plakin*; *elav-Gal4/+* (shot + Δ Plakin). ***p* < 0.001, compared with *shot^{vu}/shot³*; *elav-Gal4/+* (shot). *n* > 15 for each genotype. Error bars indicate SEM.

Having assessed the localization of these Shot deletion variants, we next tested whether expression of the transgene could rescue the NMJ overgrowth phenotype of the *shot* mutant. Expression of the full-length Shot-FL rescues the mutant, and overexpression of this transgene in a WT background does not affect NMJ growth (Figs. 1A and 2C). We also observe robust rescue with Shot- Δ Plakin and Shot- Δ Rod (Fig. 2C). Hence, the large Plakin and rod domains, which are thought to serve as spacers between the actin and microtubule binding domains, are dispensable for the function of Shot in NMJ growth control. In contrast, expression of Shot- Δ Calponin is unable to rescue the mutant phenotype. Because this protein is present in axons at levels similar to that of the Shot- Δ Plakin and Shot- Δ Rod proteins, the failure to rescue likely indicates that the absence of the Calponin homology domain in this mutant abrogates its ability

to restrain synaptic terminal growth. Finally, neither the Shot- Δ EF nor the Shot- Δ Gas2 rescues the mutant phenotype (Fig. 2C). Hence, this formally demonstrates that those domains are required for function, but this may be the result of defects in axonal localization, protein function, or both. Together, this structure function analysis demonstrates that the various binding domains at the N- and C-terminus of Shot are important for its ability to restrain synaptic growth but that the spacing between those domains is not.

Shot-dependent synaptic terminal overgrowth requires Wallenda signaling

We wished to understand the molecular mechanism by which *shot* restrains NMJ growth during development. The overgrowth in *shot* is reminiscent of *highwire* mutants where absence of the




Figure 3. *wallenda* (DLK) mutation and its downstream factors suppress the NMJ overgrowth in *shot*. **A**, Sample confocal images of muscle 4 type Ib NMJs of *shot^{vv}/shot³; elav-Gal4/+ (shot)*, *shot^{vv}/shot³; wnd²/+ (shot; wnd/+)*, *shot^{vv}/shot³; wnd²/wnd³ (shot; wnd)*, *shot^{vv}/shot³; elav-Gal4/UAS-bsk^{DN} (shot + Jnk^{DN})*, *shot^{vv}/shot³; elav-Gal4/UAS-fbz (shot + Fos^{DN})*. **B**, Quantification of the muscle 4 type Ib bouton number in WT, *shot^{vv}/shot³ (shot)*, and *shot^{vv}/shot³; wnd²/wnd³ (shot; wnd)*. **C**, Quantification of the muscle 4 type Ib bouton number in *elav-Gal4/+ (control)* and the lower two genotypes in **A**. ****** $p < 0.001$, compared with WT or control. $n > 15$ for each genotype. Scale bar, 50 μ m.

ubiquitin ligase Highwire leads to an increase in the levels of the MAPKKK Wallenda/DLK and subsequently increased downstream JNK/Fos signaling. Hence, we tested whether *wallenda* is necessary for the synaptic overgrowth phenotype of *shot*. Removing one copy of *wallenda* significantly suppresses the NMJ phenotype in *shot* mutants (Fig. 3A,B). Loss of both copies of *wallenda* in the *shot* mutant background (*shot^{vv}/shot³; wnd²/wnd³*) results in full suppression (Fig. 3A,B). Hence, *wallenda* is required for *shot*-dependent synaptic terminal overgrowth, and the degree of overgrowth depends on the dose of Wallenda/DLK, suggesting that the extent of DLK activity is instructive for synaptic terminal overgrowth.

In the *highwire* mutant, *wallenda*-dependent NMJ overgrowth requires the downstream MAP kinase JNK as well as its target, the transcription factor Fos. To investigate the role of JNK and Fos for the *shot* phenotype, we used the same dominant-negative constructs used for the analysis of *highwire* (Collins et al., 2006). Expression of a dominant-negative transgene of either *JNK* or *fos* in neurons suppresses the increase in synaptic bouton number in the *shot* mutant (Fig. 3A,C). Hence, *shot*-dependent NMJ overgrowth requires the same signaling pathway as *highwire*-dependent overgrowth, the MAP3K Wallenda/DLK, the MAPK JNK, and the transcription factor Fos.

Shot does not regulate Wallenda protein levels

In *highwire* mutants, absence of the ubiquitin ligase Highwire leads to an increase in the levels of Wallenda/DLK, which then

activates the JNK/Fos pathway. Overexpression of Wallenda/DLK can also engage the JNK/Fos pathway to trigger NMJ overgrowth (Collins et al., 2006). Hence, increasing the levels of the Wallenda/DLK can overactivate this pathway, and this is the only known mechanism to activate Wallenda/DLK signaling in *Drosophila*. Because the *shot* phenotype also requires the Wallenda/DLK pathway, we wondered whether Shot also regulates the abundance of Wallenda/DLK. We used a previously generated and validated antibody (Collins et al., 2006) to assess the levels of Wallenda in whole-brain homogenates via Western blot. In WT larvae, Wallenda levels are very low; and as previously described, they are significantly increased in the *highwire* mutant. In contrast, in *shot* mutant larvae Wallenda protein levels are similar to those observed in WT (Fig. 4A,B). Similar results were obtained using immunohistochemistry: Wallenda protein is enriched in the synaptic neuropil of the *highwire* mutant but is at WT levels in the *shot* mutant (Fig. 4C,D). Hence, although the Wallenda pathway is required for synaptic overgrowth in *shot*, the levels of Wallenda protein, unlike in *highwire* mutant, are not increased. Hence, *shot* does not function by controlling Wallenda levels.

Shot inhibits Wallenda/DLK pathway activity

The requirement of the Wallenda pathway for *shot*-dependent synaptic overgrowth is consistent with at least two models. First, the Wallenda pathway may play a permissive role in *shot*-dependent synaptic overgrowth. Here Wallenda would be necessary, but *shot* would function in an alternate pathway. Alternatively, Shot may act by inhibiting the Wallenda pathway activity. In this model, the Wallenda pathway would be upregulated in the *shot* mutant. To distinguish between these two possibilities, we probed JNK pathway activity in the *shot* mutant. JNK pathway activity can be assayed in *Drosophila* via a LacZ enhancer trap that is inserted into the JNK phosphatase *puckered* (Martín-Blanco et al., 1998), which is a transcriptional target of the JNK pathway. *puc-LacZ* is expressed at low levels in larval neurons from WT flies and is elevated when the Wallenda/DLK pathway is overactivated in *highwire* mutants (Xiong et al., 2010). We quantified the levels of *puc-LacZ* expression in neurons from both WT and *shot* mutant larvae. The level of *puc-LacZ* expression is increased approximately threefold over WT in *shot* (Fig. 5A,B), demonstrating that the JNK pathway is upregulated in the *shot* mutant.

Because the JNK pathway can be upregulated by a variety of upstream kinases (Davis, 2000), we tested whether Wallenda is necessary for activation of the JNK pathway. As previously described (Xiong et al., 2010), we were unable to generate recombinants between *wallenda* and *puc-LacZ*. Instead, we tested the role of Wallenda/DLK using a previously verified RNAi line (Xiong et al., 2010). Knockdown of *shot* expression using RNAi recapitulates the NMJ overgrowth phenotype (Fig. 1B) and also




Figure 4. Wallenda/DLK levels are not increased in *shot* mutant. **A**, Representative Western blots of extracts from larval brain and ventral nerve cords of WT, *highwire* ΔC mutant (*hiw*), and *shot^{vu}/shot³* (*shot*) probed for Wallenda and Armadillo as a loading control. **B**, The levels of the protein are quantified from three independent Western blots and then normalized to control from each blot. * $p < 0.01$, compared with WT. **C**, Staining for endogenous Wallenda in the ventral nerve cords of third-instar larvae for WT, *highwire* ΔC mutant (*highwire*), and *shot^{vu}/shot³* (*shot*). The Wallenda antibody is labeled in green, and the neuropil is labeled with synaptic marker BRP (red). The Wallenda intensity in the neuropil was measured for each genotype and normalized to WT levels. **D**, The quantification is presented as mean \pm SEM. ** $p < 0.001$, compared with WT. $n > 9$ brains for each genotype. Scale bar, 50 μ m.

leads to increased expression of *puc-lacZ* as in the classical mutant (Fig. 5). Double knockdown of *shot* and *wallenda* suppresses this increase in *puc-lacZ* expression (Fig. 5A, C). The suppression of *puc-lacZ* expression with *wallenda* RNAi is not the result of dilution of *Gal4* activity in the presence of multiple UAS lines because we failed to find suppression with two control UAS-RNAi constructs (*shot* RNAi, 3.0 ± 0.1 a.u.; *shot* RNAi + *CG13772* RNAi, 3.2 ± 0.1 a.u.; *shot* RNAi + *CG18278* RNAi, 3.6 ± 0.2 a.u.). Together, these data demonstrate that in the *shot* mutant the Wallenda/DLK signaling pathway is upregulated; and so when Shot function is unperturbed, the Wallenda/DLK pathway is inhibited. Because Shot does not function by controlling the levels of Wallenda as Highwire does, Shot must function via a novel mechanism to control the activation of Wallenda/DLK.

Cytoskeletal disruption and the activation of the Wallenda/DLK pathway

Short Stop acts as an actin-microtubule cross-linker; and in *shot* null embryos, the microtubule skeleton is less stable (Alves-Silva et al., 2012). To explore the possibility that disrupting the cyto-

skeleton might activate Wallenda/DLK, we first tested whether the inhibition of *shot* in larvae also destabilizes the cytoskeleton. We assessed *in vivo* microtubule dynamics by expressing the microtubule plus end binding-protein EB1-GFP in sensory neurons with *ppk-Gal4*. EB1-GFP labels the growing ends of microtubules in structures called “comets,” the number of which reflect the number of growing microtubules (Chen et al., 2012). Knockdown of *short stop* results in an approximate doubling of comets labeled with EB1 (control RNAi: 2.7 ± 1.5 comets, $n = 21$ neurons; *shot* RNAi: 5.3 ± 0.8 comets, $n = 14$ neurons; $p = 0.001$), demonstrating that the microtubule network is more dynamic/less stable (Fig. 6A). The role of *short stop* in stabilizing the cytoskeleton and in the activation of the Wallenda/DLK pathway in *shot* mutants is consistent with microtubule destabilization being the mechanism that activates Wallenda/DLK.

If cytoskeletal destabilization activates Wallenda/DLK activation, then other mutants that disrupt the cytoskeleton would be predicted to activate Wallenda/DLK. To this end, we targeted two subunits of the T-complex protein-1 (TCP1) complex. TCP1 is a cytosolic chaperone for tubulin and actin. Data from yeast and




Figure 5. *puc-LacZ* expression is increased in *shot* mutant ventral nerve cords in a *wallenda*-dependent manner. **A**, Larval ventral nerve cords of *puc-LacZ* / + (WT), *shot^{vu}/shot³;puc-LacZ* / + (*shot*), *elav-Gal4,UAS-dcr2* / + ; *UAS-shot-RNAi/puc-LacZ* (*shot* RNAi), and *elav-Gal4,UAS-dcr2/UAS-wnd-RNAi*; *UAS-shot-RNAi/puc-LacZ* (*shot* RNAi; *wnd* RNAi) stained for *puc-LacZ* expression in green (left) and Elav protein (red). *puc-LacZ* expression is weak in the WT ventral nerve cords but is increased in *shot* mutant and *shot* RNAi larvae. The levels of *puc-LacZ* are quantified in the neurons along the dorsal midline identified by Elav protein expression of the genotypes from **A** in addition to *elav-Gal4,UAS-dcr2* / + ; *puc-LacZ* / + (Control) are represented in **B** and **C** as mean ± SEM. ***p* < 0.001, compared with WT or control (*elav-Gal4,UAS-dcr2* / +). *n* > 9 brains for each genotype. Scale bar, 50 μm.

mammalian cell lines show that, when this complex is disrupted, the microtubule network is destabilized (Ursic et al., 1994; Grantham et al., 2006). We find that RNAi-mediated downregulation of the genes for either TCP1 α or TCP1 β , two required subunits of the TCP1 complex, also activates the JNK pathway, and this activation requires *wallenda* (Fig. 6B). Hence, this independent manipulation recapitulates our findings with *short stop* and is consistent with the model that the activation of the DLK/Wallenda pathway in *shot* is the result of destabilization of the cytoskeleton.

Shot mutants accelerate the regenerative response to injury via the Wallenda/DLK pathway

In addition to its role in synapse development, Wallenda/DLK signaling also promotes axonal regeneration after injury in worms, flies, and mammals (Hammarlund et al., 2009; Yan et al., 2009; Xiong et al., 2010; Shin et al., 2012). In *Drosophila*, loss of *highwire* leads to an increase in the levels of Wallenda/DLK that speeds the regenerative response (Xiong et al., 2010). We wondered whether it would be possible to promote regenerative sprouting by activating the Wallenda/DLK pathway without an increase in Wallenda levels. *shot* mutants have normal levels of Wallenda protein but increased pathway activity, so we tested whether this activation is sufficient to hasten the regenerative response to injury. We labeled two axons per nerve using *m12-Gal4* to drive expression of a membrane-tagged GFP, crushed peripheral nerves as previously described (Xiong et al., 2010), and assessed the regenerative potential of axons in *Drosophila* larvae. To quantify the response, we counted the fraction of injured nerves that show a large growth cone 7 h after crush (for details of blinded analysis, see Materials and Methods). Seven hours after injury, WT axons are just beginning to regenerate, with only 15% showing the regenerative response of a sprouting growth cone. On the other hand, in *shot* mutants 52% of axons have new axonal sprouts (Fig. 7A,B). We next investigated whether the improved regenerative response in *shot* requires *wallenda*. RNAi

knockdown of *shot* shows a very similar increase in the number of regenerative sprouts as the classical *shot* mutant. However, when combined with *wallenda* RNAi the enhanced regenerative response is eliminated (Fig. 7C,D). These data demonstrate that the Wallenda/DLK pathway is required for more rapid formation of regenerative axonal branches in the absence of *shot*. Hence, loss of *shot* improves the regenerative response to injury by activating the Wallenda/DLK pathway.

Discussion

The MAPKKK Wallenda/DLK is an important regulator of synaptic terminal development and the axonal response to injury (Collins et al., 2006; Hammarlund et al., 2009; Xiong et al., 2010; Shin et al., 2012). However, the mechanisms that activate this kinase are not well understood. Here we show that mutation of the spectraplakin Short stop leads to activation of Wallenda/DLK signaling, resulting in synaptic terminal overgrowth and an accelerated regenerative response to axonal injury.

A new function for the spectraplakin short stop

Spectraplakins are huge, multidomain proteins that bind to both actin and microtubules to regulate cytoskeletal dynamics. The family of spectraplakins consists of mammalian *bpag1/dystonin* (Sawamura et al., 1991) and *ACF7/MAC1* (Leung et al., 1999), *Drosophila short stop (shot)/kakapo* (Gregory and Brown, 1998), and *C. elegans vab-10* (Suozzi et al., 2012). Spectraplakins function in many cellular processes, including regulating ER-Golgi transport in mammalian sensory neurons (Ryan et al., 2012a, 2012b) and mediating polarized locomotion of skin stem cells upon injury (Wu et al., 2011). They also play an essential role in axons, as mutations in mammalian spectraplakins lead to peripheral neuropathy in both mice and humans (Bernier et al., 1995; Edvardson et al., 2012). In *Drosophila*, the spectraplakin *short stop* has been extensively studied for its role in embryonic axon outgrowth and its regulation of microtubule dynamics (Lee et al., 2000; Sanchez-Soriano et al., 2009; Alves-Silva et al., 2012). All




Figure 6. Cytoskeletal disruption and the activation of the Wallenda/DLK pathway. **A**, Growing microtubule plus-ends marked by EB1-GFP expression driven by *ppk-Gal4* in a branch of a sensory neuron in *UAS-dcr2/UAS-CG18287-RNAi; ppk-Gal4, UAS-EB1-GFP* (Control RNAi) and *UAS-dcr2/+; UAS-shot-RNAi/ppk-Gal4, UAS-EB1-GFP* (*shot* RNAi) larvae. Arrowheads indicate moving EB1-GFP comets, and asterisks indicate stationary puncta. Only the moving comets were counted in the area. Knockdown of *shot* expression results in approximate doubling of the growing microtubule plus-ends compared with control. Scale bar, 10 μ m. **B**, Larval ventral nerve cords of *elav-Gal4, UAS-dcr2/+; puc-LacZ/+* (Control), *elav-Gal4, UAS-dcr2/+; UAS-TCP1β-RNAi/puc-LacZ* (*TCP1β*-RNAi), *elav-Gal4, UAS-dcr2/+; UAS-TCP1α-RNAi/puc-LacZ* (*TCP1α*-RNAi), *elav-Gal4, UAS-dcr2/UAS-wnd-RNAi; UAS-TCP1β-RNAi/puc-LacZ* (*TCP1β*-RNAi; *wnd* RNAi), *elav-Gal4, UAS-dcr2/UAS-wnd-RNAi; UAS-TCP1α-RNAi/puc-LacZ* (*TCP1α*-RNAi; *wnd* RNAi), stained for *puc-LacZ* expression in green (left) and Elav protein (red). *puc-LacZ* expression is increased in *TCP1* RNAi larvae. **C**, The levels of *puc-LacZ* are quantified in the neurons along the dorsal midline identified by Elav protein expression are represented as mean \pm SEM. ** $p < 0.001$, compared with WT. $n > 9$ brains for each genotype. Scale bar, 50 μ m.

prior loss-of-function mutants in *shot* are embryonic lethal, and these strong alleles have severe impairments of their cytoskeleton and poor axon outgrowth, leading axons to “stop short” of their targets (Lee et al., 2000). This embryonic phenotype is in apparent contradiction to the larval phenotype we describe for the *shot^{VV}* allele, in which the synaptic terminal is overgrown with additional synaptic boutons. However the *shot^{VV}* allele is a hypomorph and motor axons successfully navigate to their targets, so this mutant must retain sufficient function to allow for axonal outgrowth. Although *shot^{VV}* behaves as a hypomorph, the molecular lesion was not identified, and so it is plausible that this allele is a neomorph and that its regulation of DLK may not reflect the normal function of the protein. However, we find that RNAi knockdown of *shot* generates the same phenotypes as *shot^{VV}* and leads to the same activation of Wallenda/DLK. Hence, both the *shot^{VV}* allele and *shot* RNAi provide evidence for a new function for *shot*, namely, as a negative regulator of Wallenda/DLK signaling. It will be interesting to determine whether mammalian spectraplakins also restrain DLK signaling and whether dysregulated MAP kinase pathways may mediate some of the phenotypes of spectraplakins mutants, such as peripheral neuropathy.

Activation of Wallenda/DLK

A series of recent studies highlights the central role of DLK in the developing and injured mammalian nervous system. DLK is required for normal developmental cell death in motor and sensory neurons (Ghosh et al., 2011; Itoh et al., 2011), for Wallerian degeneration of injured peripheral axons (Miller et al., 2009), for cell death and axon degeneration of retinal ganglion cells in models of glaucoma (Watkins et al., 2013; Welsbie et al., 2013), and for the proregenerative preconditioning response in injured DRG axons (Shin et al., 2012). Because DLK appears to be central to the neuronal injury response, there is great interest in understanding its mechanism of activation. In particular, it is important to understand how axon injury leads to the activation of DLK.

To date, methods that increase the levels of DLK are the best understood mechanism for increasing DLK activity. In worms, flies, and mice, loss of the PHR ubiquitin ligase leads to an increase in the levels of DLK (Nakata et al., 2005; Collins et al., 2006; Babetto et al., 2013); and in worms and flies, there are extensive data demonstrating that this activates the kinase. Similarly, in both worms and flies, the overexpression of DLK is sufficient to




Figure 7. *shot* mutants have enhanced axonal sprouting after injury. Axons are labeled by driving expression of *UAS-mCD8-GFP* by *m12-Gal4*. Axons from (**A**) WT animals do not yet form extensive new branches by 7 h after injury, whereas in *shot^{vu}/shot³* (*shot*) mutants a large growth cone with multiple sprouting sites can be seen more frequently than in WT ($p < 0.001$, χ^2 test, $n > 30$ axons for each genotype). The number of blunt versus sprouting axonal stumps was counted, and their frequencies are presented in **B**. **C**, Same analysis was done on *UAS-dcr2*; *UAS-mCD8-GFP*, *m12-Gal4* + (control), *UAS-dcr2*; *UAS-mCD8-GFP*, *m12-Gal4/UAS-shot-RNAi*; (*shot* RNAi), *UAS-dcr2*; *UAS-wnd-RNAi* +; *UAS-mCD8-GFP*, *m12-Gal4* + (*wnd* RNAi), and *UAS-dcr2*; *UAS-wnd-RNAi/UAS-mCD8-GFP*, *m12-Gal4*; *UAS-shot-RNAi* + (*shot* RNAi; *wnd* RNAi) and quantified in **D**. $n > 50$ axons for each genotype. Scale bar, 25 μ m.

activate the DLK signaling pathway. In *Drosophila*, injury leads to a loss of the PHR ubiquitin ligase Highwire (Xiong et al., 2010), potentially via autophagosomal degradation (Shen and Ganetzky, 2009; Tian et al., 2011), which in turn leads to an increase in DLK and may be a method of injury-induced activation. In mammals, a positive feedback loop between DLK and JNK inhibits Phr1-dependent degradation of DLK, increasing the levels of DLK and activating the pathway (Huntwork-Rodriguez et al., 2013). In addition, a calcium-dependent activation mechanism was recently demonstrated in *C. elegans* (Yan and Jin, 2012), which is very exciting because calcium influx is an early step after axon injury. However, the key hexapeptide sequence that mediates this calcium-dependent regulation is absent from both *Drosophila* and mouse DLK, suggesting that additional activation mechanisms for DLK may exist. Indeed, our data show that loss of the spectraplaklin *shot* can also activate DLK and

leads to the hypothesis that cytoskeletal disruptions may activate DLK. Our findings demonstrate that loss of function of *shot* leads to activation of Wallenda/DLK without a concomitant increase in the levels of Wallenda/DLK. Hence, loss of *shot* is not acting upstream or in concert with Highwire because loss of Highwire or components of the Highwire ubiquitin ligase complex lead to increased levels of Wallenda/DLK (Collins et al., 2006; Wu et al., 2007). The *shot* mutant is, to our knowledge, the first manipulation that activates Wallenda/DLK signaling in *Drosophila* without altering the levels of Wallenda/DLK. Hence, loss of *shot* must activate Wallenda/DLK via a novel mechanism. We hypothesize that this mechanism is related to the biochemical function of Shot, which is to stabilize the cytoskeleton by simultaneously binding both actin and microtubules. Prior studies demonstrate that *shot* null mutants have a destabilized microtubule network (Alves-Silva et al., 2012), and we demonstrate

that the microtubule network is more dynamic in *shot* RNAi knock-down larvae. We propose that a destabilized cytoskeleton activates Wallenda/DLK. Consistent with this model, we show that mutations in either of two subunits of the TCP-1 complex, which like Shot regulates both the actin and microtubule cytoskeleton, leads to activation of DLK signaling. By demonstrating this activation of DLK signaling, our results support and extend the work of Bounoutas et al. (2011) who demonstrated that microtubule disruption leads to DLK-dependent changes in protein levels in *C. elegans*. Moreover, our findings are consistent with studies in mammalian cell culture demonstrating that drugs that destabilize microtubules can activate MAP kinase signaling (Wang et al., 1998; Stone and Chambers, 2000; Yang et al., 2007), as well as studies in *Drosophila* showing that genetic disruption of the cytoskeleton can activate JNK signaling (Mas-saro et al., 2009).

Axonal injury as a result of trauma or neurotoxic insults, such as chemotherapy drug treatment, is accompanied by a change in microtubule network stability. We propose a model in which DLK functions as a sensor of microtubule network stability. When the cytoskeleton is destabilized as a result of injury, DLK will be activated. The consequence of that activation will depend on downstream signaling pathways and may differ by cellular compartment. For example, DLK in the distal axon will promote axonal degeneration (Miller et al., 2009), whereas DLK activation in proximal axons will facilitate the retrograde transport of injury signals that can activate regenerative and/or apoptotic gene expression programs (Shin et al., 2012; Watkins et al., 2013).

Promoting regeneration by activating DLK

In the mammalian PNS, DLK is required for the preconditioning response that boosts the efficacy of peripheral DRG axon regeneration after a prior nerve injury (Shin et al., 2012). In both worms and flies, activation of DLK by increasing its abundance improves the regenerative response in the absence of a prior nerve injury (Hammarlund et al., 2009; Xiong et al., 2010). Hence, it is attractive to speculate that activation of DLK in the absence of injury may also improve regeneration in mammalian axons. Our findings with *shot* suggest that relatively mild disruptions to the axonal cytoskeleton can activate DLK and accelerate the regenerative response in *Drosophila* in the absence of a prior trauma. Future studies will test whether pharmacological agents that disrupt the cytoskeleton can activate DLK in mammalian neurons and whether such activation promotes axon regeneration.

In conclusion, our study demonstrates that, in the absence of Shot, Wallenda/DLK signaling is activated resulting in synaptic terminal overgrowth and more rapid regenerative axonal sprouting. The role of Shot as an actin-microtubule cross-linker suggests that Wallenda/DLK is activated by cytoskeletal disruption and suggests novel approaches for controlling DLK activity in the injured or diseased nervous system.

References

- Alves-Silva J, Sánchez-Soriano N, Beaven R, Klein M, Parkin J, Millard TH, Bellen HJ, Venken KJ, Ballestrin C, Kammerer RA, Prokop A (2012) Spectraplakins promote microtubule-mediated axonal growth by functioning as structural microtubule-associated proteins and EB1-dependent +TIPs (tip interacting proteins). *J Neurosci* 32:9143–9158. [CrossRef Medline](#)
- Babetto E, Beirowski B, Russler EV, Milbrandt J, DiAntonio A (2013) The Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. *Cell Rep* 3:1422–1429. [CrossRef Medline](#)
- Bernier G, Brown A, Dalpé G, De Repentigny Y, Mathieu M, Kothary R (1995) Dystonin expression in the developing nervous system predominates in the neurons that degenerate in dystonia musculorum mutant mice. *Mol Cell Neurosci* 6:509–520. [CrossRef Medline](#)
- Bloom AJ, Miller BR, Sanes JR, DiAntonio A (2007) The requirement for Phr1 in CNS axon tract formation reveals the corticostriatal boundary as a choice point for cortical axons. *Genes Dev* 21:2593–2606. [CrossRef Medline](#)
- Bottenberg W, Sanchez-Soriano N, Alves-Silva J, Hahn I, Mende M, Prokop A (2009) Context-specific requirements of functional domains of the Spectraplaklin Short stop in vivo. *Mech Dev* 126:489–502. [CrossRef Medline](#)
- Bounoutas A, Kratz J, Emtage L, Ma C, Nguyen KC, Chalfie M (2011) Microtubule depolymerization in *Caenorhabditis elegans* touch receptor neurons reduces gene expression through a p38 MAPK pathway. *Proc Natl Acad Sci U S A* 108:3982–3987. [CrossRef Medline](#)
- Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* 118:401–415. [Medline](#)
- Chen L, Stone MC, Tao J, Rolls MM (2012) Axon injury and stress trigger a microtubule-based neuroprotective pathway. *Proc Natl Acad Sci U S A* 109:11842–11847. [CrossRef Medline](#)
- Collins CA, Wairkar YP, Johnson SL, DiAntonio A (2006) Highwire restrains synaptic growth by attenuating a MAP kinase signal. *Neuron* 51:57–69. [CrossRef Medline](#)
- Culican SM, Bloom AJ, Weiner JA, DiAntonio A (2009) Phr1 regulates retinogeniculate targeting independent of activity and ephrin-A signalling. *Mol Cell Neurosci* 41:304–312. [CrossRef Medline](#)
- Daniels RW, Collins CA, Gelfand MV, Dant J, Brooks ES, Krantz DE, DiAntonio A (2004) Increased expression of the *Drosophila* vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. *J Neurosci* 24:10466–10474. [CrossRef Medline](#)
- Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. *Cell* 103:239–252. [CrossRef Medline](#)
- DiAntonio A, Haghighi AP, Portman SL, Lee JD, Amaranto AM, Goodman CS (2001) Ubiquitination-dependent mechanisms regulate synaptic growth and function. *Nature* 412:449–452. [CrossRef Medline](#)
- Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oettel S, Scheiblaue S, Couto A, Marra V, Keleman K, Dickson BJ (2007) A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*. *Nature* 448:151–156. [CrossRef Medline](#)
- Edvardson S, Cinnamon Y, Jala C, Shaag A, Maayan C, Axelrod FB, Elpeleg O (2012) Hereditary sensory autonomic neuropathy caused by a mutation in dystonin. *Ann Neurol* 71:569–572. [CrossRef Medline](#)
- Eresh S, Riese J, Jackson DB, Bohmann D, Bienz M (1997) A CREB-binding site as a target for decapentaplegic signalling during *Drosophila* endoderm induction. *EMBO J* 16:2014–2022. [CrossRef Medline](#)
- Ghosh AS, Wang B, Pozniak CD, Chen M, Watts RJ, Lewcock JW (2011) DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity. *J Cell Biol* 194:751–764. [CrossRef Medline](#)
- Grantham J, Brackley KI, Willison KR (2006) Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. *Exp Cell Res* 312:2309–2324. [CrossRef Medline](#)
- Gregory SL, Brown NH (1998) kakapo, a gene required for adhesion between and within cell layers in *Drosophila*, encodes a large cytoskeletal linker protein related to plectin and dystrophin. *J Cell Biol* 143:1271–1282. [CrossRef Medline](#)
- Hammarlund M, Nix P, Hauth L, Jorgensen EM, Bastiani M (2009) Axon regeneration requires a conserved MAP kinase pathway. *Science* 323:802–806. [CrossRef Medline](#)
- Huntwork-Rodriguez S, Wang B, Watkins T, Ghosh AS, Pozniak CD, Bustos D, Newton K, Kirkpatrick DS, Lewcock JW (2013) JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis. *J Cell Biol* 202:747–763. [CrossRef Medline](#)
- Itoh A, Horiuchi M, Wakayama K, Xu J, Bannerman P, Pleasure D, Itoh T (2011) ZPK/DLK, a mitogen-activated protein kinase kinase kinase, is a critical mediator of programmed cell death of motoneurons. *J Neurosci* 31:7223–7228. [CrossRef Medline](#)
- Klapper R (2000) The longitudinal visceral musculature of *Drosophila melanogaster* persists through metamorphosis. *Mech Dev* 95:47–54. [CrossRef Medline](#)
- Kolodziej PA, Jan LY, Jan YN (1995) Mutations that affect the length, fasciculation, or ventral orientation of specific sensory axons in the *Drosophila* embryo. *Neuron* 15:273–286. [CrossRef Medline](#)
- Lee S, Kolodziej PA (2002) Short Stop provides an essential link between F-actin and microtubules during axon extension. *Development* 129:1195–1204. [Medline](#)
- Lee S, Harris KL, Whittington PM, Kolodziej PA (2000) short stop is allelic to

- kakapo, and encodes rod-like cytoskeletal-associated proteins required for axon extension. *J Neurosci* 20:1096–1108. [Medline](#)
- Leung CL, Sun D, Zheng M, Knowles DR, Liem RK (1999) Microtubule actin cross-linking factor (MACF): a hybrid of dystonin and dystrophin that can interact with the actin and microtubule cytoskeletons. *J Cell Biol* 147:1275–1286. [CrossRef Medline](#)
- Lewcock JW, Genoud N, Lettieri K, Pfaff SL (2007) The ubiquitin ligase Phr1 regulates axon outgrowth through modulation of microtubule dynamics. *Neuron* 56:604–620. [CrossRef Medline](#)
- Marrus SB, Portman SL, Allen MJ, Moffat KG, DiAntonio A (2004) Differential localization of glutamate receptor subunits at the *Drosophila* neuromuscular junction. *J Neurosci* 24:1406–1415. [CrossRef Medline](#)
- Martin-Blanco E, Gampel A, Ring J, Virdee K, Kirov N, Tolkovsky AM, Martinez-Arias A (1998) puckered encodes a phosphatase that mediates a feedback loop regulating JNK activity during dorsal closure in *Drosophila*. *Genes Dev* 12:557–570. [CrossRef Medline](#)
- Massaro CM, Pielage J, Davis GW (2009) Molecular mechanisms that enhance synapse stability despite persistent disruption of the spectrin/ankyrin/microtubule cytoskeleton. *J Cell Biol* 187:101–117. [CrossRef Medline](#)
- Miller BR, Press C, Daniels RW, Sasaki Y, Milbrandt J, DiAntonio A (2009) A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. *Nat Neurosci* 12:387–389. [CrossRef Medline](#)
- Nakata K, Abrams B, Grill B, Goncharov A, Huang X, Chisholm AD, Jin Y (2005) Regulation of a DLK-1 and p38 MAP kinase pathway by the ubiquitin ligase RPM-1 is required for presynaptic development. *Cell* 120:407–420. [CrossRef Medline](#)
- Nix P, Hisamoto N, Matsumoto K, Bastiani M (2011) Axon regeneration requires coordinate activation of p38 and JNK MAPK pathways. *Proc Natl Acad Sci U S A* 108:10738–10743. [CrossRef Medline](#)
- Röper K, Brown NH (2003) Maintaining epithelial integrity: a function for gigantic spectraplakins in adherens junctions. *J Cell Biol* 162:1305–1315. [CrossRef Medline](#)
- Röper K, Gregory SL, Brown NH (2002) The “spectraplakins”: cytoskeletal giants with characteristics of both spectrin and plakins families. *J Cell Sci* 115:4215–4225. [CrossRef Medline](#)
- Ryan SD, Bhanot K, Ferrier A, De Repentigny Y, Chu A, Blais A, Kothary R (2012a) Microtubule stability, Golgi organization, and transport flux require dystonin- α -MAP1B interaction. *J Cell Biol* 196:727–742. [CrossRef Medline](#)
- Ryan SD, Ferrier A, Kothary R (2012b) A novel role for the cytoskeletal linker protein dystonin in the maintenance of microtubule stability and the regulation of ER-Golgi transport. *Bioarchitecture* 2:2–5. [CrossRef Medline](#)
- Sanchez-Soriano N, Travis M, Dajas-Bailador F, Gonçalves-Pimentel C, Whitmarsh AJ, Prokop A (2009) Mouse ACF7 and *drosophila* short stop modulate filopodia formation and microtubule organization during neuronal growth. *J Cell Sci* 122:2534–2542. [CrossRef Medline](#)
- Sanyal S (2009) Genomic mapping and expression patterns of C380, OK6 and D42 enhancer trap lines in the larval nervous system of *Drosophila*. *Gene Expr Patterns* 9:371–380. [CrossRef Medline](#)
- Sawamura D, Li K, Chu ML, Uitto J (1991) Human bullous pemphigoid antigen (BPAG1): amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. *J Biol Chem* 266:17784–17790. [Medline](#)
- Schaefer AM, Hadwiger GD, Nonet ML (2000) rpm-1, a conserved neuronal gene that regulates targeting and synaptogenesis in *C. elegans*. *Neuron* 26:345–356. [CrossRef Medline](#)
- Shen W, Ganetzky B (2009) Autophagy promotes synapse development in *Drosophila*. *J Cell Biol* 187:71–79. [CrossRef Medline](#)
- Shin JE, Cho Y, Beirowski B, Milbrandt J, Cavalli V, DiAntonio A (2012) Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. *Neuron* 74:1015–1022. [CrossRef Medline](#)
- Stone AA, Chambers TC (2000) Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. *Exp Cell Res* 254:110–119. [CrossRef Medline](#)
- Suozzi KC, Wu X, Fuchs E (2012) Spectraplakins: master orchestrators of cytoskeletal dynamics. *J Cell Biol* 197:465–475. [CrossRef Medline](#)
- Tian X, Li J, Valakh V, DiAntonio A, Wu C (2011) *Drosophila* Rael controls the abundance of the ubiquitin ligase Highwire in post-mitotic neurons. *Nat Neurosci* 14:1267–1275. [CrossRef Medline](#)
- Tian X, Wu C (2013) The role of ubiquitin-mediated pathways in regulating synaptic development, axonal degeneration and regeneration: insights from fly and worm. *J Physiol* 591:3133–3143. [CrossRef Medline](#)
- Ursic D, Sedbrook JC, Himmel KL, Culbertson MR (1994) The essential yeast Tcp1 protein affects actin and microtubules. *Mol Biol Cell* 5:1065–1080. [CrossRef Medline](#)
- Valakh V, Naylor SA, Berns DS, DiAntonio A (2012) A large-scale RNAi screen identifies functional classes of genes shaping synaptic development and maintenance. *Dev Biol* 366:163–171. [CrossRef Medline](#)
- Wagh DA, Rasse TM, Asan E, Hofbauer A, Schwenkert I, Dürrbeck H, Buchner S, Dabauvalle MC, Schmidt M, Qin G, Wichmann C, Kittel R, Sigrist SJ, Buchner E (2006) Bruchpilot, a protein with homology to ELKS/CAST, is required for structural integrity and function of synaptic active zones in *Drosophila*. *Neuron* 49:833–844. [CrossRef Medline](#)
- Wan HI, DiAntonio A, Fetter RD, Bergstrom K, Strauss R, Goodman CS (2000) Highwire regulates synaptic growth in *Drosophila*. *Neuron* 26:313–329. [CrossRef Medline](#)
- Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J (1998) Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. *J Biol Chem* 273:4928–4936. [CrossRef Medline](#)
- Watkins TA, Wang B, Huntwork-Rodriguez S, Yang J, Jiang Z, Eastham-Anderson J, Modrusan Z, Kaminker JS, Tessier-Lavigne M, Lewcock JW (2013) DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. *Proc Natl Acad Sci U S A* 110:4039–4044. [CrossRef Medline](#)
- Weber U, Paricio N, Mlodzik M (2000) Jun mediates Frizzled-induced R3/R4 cell fate distinction and planar polarity determination in the *Drosophila* eye. *Development* 127:3619–3629. [Medline](#)
- Welsbie DS, Yang Z, Ge Y, Mitchell KL, Zhou X, Martin SE, Berlinicke CA, Hackler L Jr, Fuller J, Fu J, Cao LH, Han B, Auld D, Xue T, Hirai S, Germain L, Simard-Bisson C, Blouin R, Nguyen JV, Davis CH, et al. (2013) Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. *Proc Natl Acad Sci U S A* 110:4045–4050. [CrossRef Medline](#)
- Wu C, Wairkar YP, Collins CA, DiAntonio A (2005) Highwire function at the *Drosophila* neuromuscular junction: spatial, structural, and temporal requirements. *J Neurosci* 25:9557–9566. [CrossRef Medline](#)
- Wu C, Daniels RW, DiAntonio A (2007) Dfns collaborates with Highwire to down-regulate the Wallenda/DLK kinase and restrain synaptic terminal growth. *Neural Dev* 2:16. [CrossRef Medline](#)
- Wu X, Shen QT, Oristian DS, Lu CP, Zheng Q, Wang HW, Fuchs E (2011) Skin stem cells orchestrate directional migration by regulating microtubule-ACF7 connections through GSK3 β . *Cell* 144:341–352. [CrossRef Medline](#)
- Xiong X, Collins CA (2012) A conditioning lesion protects axons from degeneration via the Wallenda/DLK MAP kinase signaling cascade. *J Neurosci* 32:610–615. [CrossRef Medline](#)
- Xiong X, Wang X, Ewanek R, Bhat P, DiAntonio A, Collins CA (2010) Protein turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. *J Cell Biol* 191:211–223. [CrossRef Medline](#)
- Xiong X, Hao Y, Sun K, Li J, Li X, Mishra B, Soppina P, Wu C, Hume RI, Collins CA (2012) The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein. *PLoS Biol* 10:e1001440. [CrossRef Medline](#)
- Yan D, Jin Y (2012) Regulation of DLK-1 kinase activity by calcium-mediated dissociation from an inhibitory isoform. *Neuron* 76:534–548. [CrossRef Medline](#)
- Yan D, Wu Z, Chisholm AD, Jin Y (2009) The DLK-1 kinase promotes mRNA stability and local translation in *C. elegans* synapses and axon regeneration. *Cell* 138:1005–1018. [CrossRef Medline](#)
- Yang Y, Zhu X, Chen Y, Wang X, Chen R (2007) p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in colchicine-induced cortical neurons apoptosis. *Eur J Pharmacol* 576:26–33. [CrossRef Medline](#)
- Yao KM, White K (1994) Neural specificity of elav expression: defining a *Drosophila* promoter for directing expression to the nervous system. *J Neurochem* 63:41–51. [CrossRef Medline](#)
- Zhen M, Huang X, Bamber B, Jin Y (2000) Regulation of presynaptic terminal organization by *C. elegans* RPM-1, a putative guanine nucleotide exchanger with a RING-H2 finger domain. *Neuron* 26:331–343. [CrossRef Medline](#)